Posted on

TIGIT, PD-L1, CD112R & more: IHC-marker Immuno-Oncology

We develop antibodies for the tissue-based detection of immune checkpoint markers

dianova concentrates on development of new antibody clones for the tissue-based detection of cancer immunology biomarkers. dianova’s vision is to provide the best antibodies for immunohistochemical analysis of biomarker expression profiles to better understand the complex interaction of immune cells and the tumor cells in patient tissue. dianova believes that multiplexed IHC-assessment of immune checkpoint targets in tumor tissues is indispensable for cancer research.

Learn more about TIGIT & cancer immunology checkpoint blockade